The role of these receptors in aortic aneurysm progression remains controversial. In a genetic mouse model of thoracic aneurysm, disruption of the AT2 gene in Fbn C1039G/+ mice resulted in worsening of aortic wall architecture. 15 Moreover, beneficial effects of losartan on aneurysm progression were lost. However, Daugherty et al 16 showed in the Ang II (angiotensin II)-induced mouse model that AT 2 R deficiency had no effect on either aortic aneurysms or atherosclerosis.
Recent studies with direct pharmacological stimulation of the AT 2 R using the selective, nonpeptide AT 2 R agonist, Compound 21 (C21), demonstrated that in the vasculature the AT 2 R exerts antiproliferative, 17 antifibrotic, 18, 19 and antiatherosclerotic effects. 20 Moreover, AT 2 R stimulation prevented inflammation, [21] [22] [23] proteolysis, 21, 22 apoptosis, 22 and extracellular matrix tissue regeneration processes. 13 Taken collectively, the antifibrotic, antiproteolytic, and anti-inflammatory features of the AT 2 R can prevent outward remodeling in AAA. On this basis, we hypothesized that AT 2 R activation reduces aneurysmal growth in AAA. To this end, we explored the effect of treatment with C21 in the experimental AAA model in the rat.
Methods
The authors declare that all supporting data are available within the article and in the online-only Data Supplement.
Ethics Statement
This study was performed in strict accordance with national and European guidelines for animal experiments with approval by the ethics commission of the regulatory authorities of the City of Berlin, Germany, the Landesamt for Gesundheit und Soziales (registration number G0002/16).
Experimental Protocol
AAA was induced by elastase perfusion as previously described. 4, 22, 24 Briefly, the isolated segment of the infrarenal aorta was perfused with elastase (14 U, Type I; Sigma-Aldrich Chemie, Darmstadt, Germany) for 40 minutes under isoflurane anesthesia. Male Wistar rats were randomly assigned to the following groups: C21 treatment (0.03 mg/ kg daily IP; n=7), vehicle treatment (0.9% NaCl IP; n=8) and shamoperated controls (n=6). Treatment was started after aneurysm induction (AI). C21 was kindly provided by Vicore Pharma (Gothenburg, Sweden).
Analysis of Ultrasonic and Hemodynamic Parameters
Transabdominal ultrasound measurements of aortic diameters were performed preoperatively, and on day 7 and day 14 postoperatively, using the Vevo 3100 (VisualSonics Inc, Toronto, Canada) in blinded manner.
Systolic blood pressure was measured in conscious rats before surgery and on days 7 and 14 after AI by the tail-cuff method (ADInstruments, Oxford, United Kingdom). Invasive hemodynamic assessment was performed at the end of the study using a fiberoptic pressure transducer catheter (Samba Sensors, Sweden) and Chart5 software (blood pressure module) for analysis as previously described. 22 Pulse wave analysis was performed as previously described.
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Histology and Immunohistochemistry
Paraffin-embedded cross-sections of abdominal aorta (4 µm) were stained (Weigert method) and analyzed by quantitative morphometry (Biorevo BZ-9000, Keyence Japan). Immunohistochemistry was performed with following primary antibodies: MMP9 (matrix metalloproteinase 9), Snai1, NFκB (nuclear factor κB), TGF-β1 (transforming growth factor-β1), IL-1β (interleukin-1β), MLKL (mixed lineage kinase domain-like), CD68, ANG/Ang I/Ang II, AT 2 R, and CD4. The AT 2 R and CD4 colocalization were studied by fluorescence microscopy. Details of immunohistochemistry and antibodies are described in the online-only Data Supplement.
Western Blot Analysis and ELISA
Immunoblotting for MMP9, NFκB, TIMP-1 (tissue inhibitor of MMP-1), TGF-β1, IL-1β, MLKL, Snai1, SLUG was performed according to standard protocols. 22 Concentration of TGF-β1, MCP-1 (monocyte chemoattractant protein-1), IL-1β, and TNF-α in plasma was determined by ELISA. Details of antibodies are presented in the online-only Data Supplement.
Statistical Analysis
Results are expressed as mean±SD. Multiple comparisons were analyzed using 2-way repeated measures ANOVA followed by Tukey multiple comparisons test. Two-group comparisons were analyzed by the 2-tailed Student unpaired t test for independent samples. Statistical analysis was performed using GraphPad Prism 6 (GraphPad Software Inc, La Jolla, CA)
Results
Abdominal Aortic Diameter and Aortic Wall Characteristics
Aortic diameters in sham-treated, placebo-treated, and C21-treated groups are shown in Figure 1 . On day 7 after AI, the infrarenal aortic diameter increased 1. Aortic wall distensibility measured at the aneurysmal site in the vehicle group decreased after AI by 72% (P<0.0001; Figure 2A ). Values in the sham group remained unchanged. In C21-treated animals, the decrease of aortic distensibility after AI was less compared with vehicle group on day 7 (P<0.05). This effect was enhanced on day 14 (P<0.01; Figure 2B ).
Pulse propagation velocity measured at the aneurysmal site ( Figure 2C ) also showed differences between groups ( Figure 2D ). In the vehicle group, pulse propagation velocity increased 1.72-fold (P<0.05), while C21 prevented this increase. Aortic distensibility and pulse propagation velocity when measured suprarenally, distal to renal artery and proximal to bifurcation were unaffected by AI and C21.
Hemodynamic Parameters
Systolic blood pressure was assessed in conscious rats at different time points (Table S1 in the online-only Data Supplement). AI had no influence on blood pressure and treatment with C21 did not modify blood pressure significantly ( Figure S1A ).
These results were confirmed by directly measurements via Samba catheter. AI did not change systolic and diastolic blood pressure in the vehicle-treated group compared with sham-operated animals (Table S1 ). Similarly, treatment with C21 did not influence systolic and diastolic pressure as compared with vehicle (Table S1 ).
C21 treatment significantly decreased pulse pressure (26.8±1.4 versus 33.5±2.5 mm Hg; P<0.05) as compared with vehicle group (Table S1) .
Aneurysm induced a significant decrease of peak systolic velocity, mean velocity, and velocity time integral, which reflect blood flow ( Figure 3B through 3D). C21 treatment normalized these parameters ( Figure 3B through 3D). End-diastolic velocity and the indices associated with it, such as resistive index and pulsatile index, remained unaffected on day 14 after AI and C21 treatment ( Figure S1B ). Aside from aneurysm, the velocities were not altered.
Morphological Studies
The cross-sectional area of the aortic lumen of vehicletreated rats revealed a dilatation with remodeling in the media and adventitia ( Figure 4A and 4B). Aneurysms were characterized by thinning of the aortic wall, fragmentations, and ruptures of elastic lamellae ( Figure 4A and 4B). The aortae of vehicle-treated rats exhibited less elastic lamellae compared with sham-operated animals ( Figure 4C ). Moreover, in the adventitial layer, the cross-sectional area of lymphatic nodes was significantly higher in aneurysmatic compared with healthy aorta indicating an inflammatory process ( Figure 4B and 4D).
After C21 treatment, the aortic diameter was smaller and there was less fragmentation of elastic lamellae and less remodeling in the aortic wall ( Figure 4A and 4B). C21 treatment decreased the number of inflammatory infiltrates, as well as the size of lymphatic nodes in the adventitial space ( Figure 4D ) and abolished the decrease in media thickness (P<0.01; Figure 4E) .
Immunohistochemically, the Ang II precursors were expressed after AI in the adventitial layer ( Figure S2A ) and treatment with C21 reduced its expression ( Figure S2B ). The AT 2 R was also highly expressed in the adventitia after AI, colocalizing with inflammatory cells, fat cells, and vasa vasorum ( Figure S3A and S3B) . In sham-operated animals, the AT 2 R was found in the endothelial layer and only single cells were stained in the adventitia (data not shown). Colocalization studies for the AT 2 R and CD4 + lymphocytes showed that specific signals for the AT 2 R were distributed in the adventitia and along the vasa vasorum ( Figure S4A and S4B). CD4 + cells were also found mostly in the adventitia ( Figure S4C ). The colocalized signals were pointing at CD4+ cells expressing the AT 2 R ( Figure S4D ).
Regulation of Proteolysis, Inflammation, Cell Death, and Endothelial-Mesenchymal Transition Markers
In AAA, the active form of MMP9 (≈82 kDa) was upregulated (1.5-fold) and localized in the media and in the adventitia within the inflammatory cells ( Figure 5A and 5B). C21 treatment decreased MMP9 expression to levels of the sham group (P<0.05; Figure 5A ). The expression of the natural MMP9 inhibitor, TIMP-1, was also increased in the AAA animals and downregulated by C21 (P<0.05).
The inflammatory cytokine IL-1β and transcription factor NFκB were significantly increased (P<0.01; P<0.05, respectively) in the aorta of the AAA group, localizing with the inflammatory cells in the media and adventitia ( Figure 5B ). Concomitantly, C21 treatment reduced the expression of both IL-1β (4.9-fold; P<0.05) and NFκB (2.4-fold; P<0.05).
Interestingly, CD68
+ macrophages were present in the damaged endothelial layer of AAA animals (data not shown).
TGF-β1 protein was also regulated by AI and C21 treatment. In Western blot, we detected 2 bands of TGF-β1: a peptide ≈60 kDa and a dimer ≈44 kDa ( Figure 5A ). Both forms were upregulated in AAA (P<0.05; P<0.001, respectively). TGF-β1 was strongly expressed in the adventitia but also in medial layer as shown in Figure 5C . C21 attenuated this increase in TGF-β1 (1.8-fold lower 60 kDa band; P<0.05, and 2.5-fold 44 kDa compared with vehicle; P<0.01; Figure 5A ).
Because TGF-β1 may initiate endothelial-mesenchymal transition, the relevant transcriptional factors SLUG and Snai1 were analyzed. Whereas C21 attenuated the decrease in SLUG (P<0.05), no impact on Snai1 expression was found ( Figure 5A ).
Activation of the pseudokinase MLKL is known to trigger necroptosis, a form of programmed cell death. MLKL was expressed only after AI ( Figure 5A ). C21 decreased MLKL 2-fold as compared with the vehicle group ( Figure 5A ). MLKL was found mostly in the media colocalizing with vascular smooth muscle cells and inflammatory cells ( Figure 5B ).
Regulation of Cytokines in Serum
The concentrations of MCP-1, TNF-α, IL-6 in the serum were not significantly regulated, neither in the vehicle nor in C21 group. The increase of TGF-β1 concentrations in the vehicle group (P<0.01) was significantly reduced by treatment with C21 (P<0.05; Figure 5D ).
Discussion
In the present study, we provide evidence that AT 2 R stimulation prevents aneurysm progression in experimental AAA in the rat. Administration of the AT 2 R agonist, C21, significantly reduced aortic dilatation and preserved function and structural morphology of the aorta.
The role of the AT 2 R in aortic aneurysm progression has been discussed controversially. Habashi et al 15 showed that a loss of AT 2 R expression accelerated the aberrant growth and rupture of the aorta in a murine model of Marfan syndrome. In contrast, genetic AT 2 R deficiency did not affect Ang IIinduced thoracic and abdominal aneurysms and atherosclerosis, as demonstrated by Daugherty et al. 16 We investigated potential antianeurysmatic effects of the direct AT 2 R stimulation with the nonpeptide AT 2 R agonist, C21. We used an elastase-perfused model of aneurysm that is not associated with angiotensin. AI resulted in aortic dilatation and structural changes of the tunica media, such as elastin degradation and fragmentation of elastic fibers. The vascular damage was associated with an increased inflammatory and proteolytical status of the aorta, known to be essential for aneurysm progression. 26 We demonstrate that stimulation of the AT 2 R prevents aortic dilatation and destruction of the aorta. Reduced outward remodeling observed after C21 treatment correlated with structural morphology of the aorta. Fragmentations and ruptures of elastic lamellae, thinning of the aortic wall, cystic degeneration, and inflammatory infiltrations were minimal in the C21-treated group.
The progression and rupture of aneurysms are known to be influenced by hemodynamic factors, especially by blood pressure. 27 In the present study, treatment with C21 had no impact on blood pressure, which is in agreement with previous investigations. 28 Nevertheless, in consensus with other studies, 18, 19, 21 C21 treatment significantly ameliorated the AAA-induced increase of pulse pressure and pulse propagation velocity, an index of aortic stiffness. Arterial stiffness is linked to aneurysm formation 29, 30 and may contribute to different manifestations of acute aortic dissection in humans. 31 A favorable effect of the AT 2 R stimulation on arterial stiffness by AAA may be explained by preserved structural morphology because of antiproteolysis, antiinflammation, and prevention of vascular smooth muscle cells death.
In addition, the present study demonstrates effects of treatment with C21 on biomechanical vascular properties, especially on aortic wall distensibility in the AAA. Consistent with aortic stiffness modulations and data from human studies, 32, 33 aortic wall distensibility decreased in the aneurysm and was unaffected outside AAA. Positive effects of AT 2 R stimulation on distensibility coincided with maintained vascular integrity.
AAA is also characterized by alterations in aortic flow and high wall shear stress. 27 In our study, aneurysm was associated with a decrease of peak systolic velocity, mean velocity, and velocity time integral that reflect blood flow. C21 treatment restored all these parameters, which are known to be independent risk factors for aortic rupture. 34, 35 These beneficial effects may be partly explained by preserved geometry of the aneurysm-segment, as well as preserved wall strength. End-diastolic velocity and the indices associated with it, such as resistive index and pulsatile index, which are strong surrogates for stenosis, remained unaffected by AI and C21 treatment. Biochemical analyses provide further evidence for antianeurysmatic mechanisms of AT 2 R activation. Degradation of extracellular matrix within the aortic wall is a hallmark of AAA, 26 and MMP9 is considered one of the predominant proteinases. 36 MMP9 was activated in AAA, and this activation was abolished by C21 treatment. As previously shown in cardiac fibroblasts, the inhibitory effect of C21 on MMP9 activity is AT 2 R specific, hence reversible by the AT 2 R antagonist PD123319. 21 The MMP9/TIMP ratio was positively affected by C21 and the protease/antiprotease equilibrium was modified in favor of decreased proteolysis.
An important factor of aneurysm development is the ubiquitous inflammatory cell infiltrate, which was demonstrated in human AAA 14, 37 and in our experimental model. The expression of the AT 2 Rs was found in the adventitia, colocalizing with the vasa vasorum and inflammatory cells.
We also confirmed studies by Wang et al 38 demonstrating a colocalization of the AT 2 R with CD4 + lymphocytes. These cells have been shown to have protective effect in thoracic aneurysm through inhibition of growth, apoptosis, and MMP2 expression.
C21 treatment decreased the number of inflammatory infiltrates and lymphatic nodes in the adventitial space. This findings support the accepted anti-inflammatory role of the AT 2 R. 39 In particular, C21 treatment reduced the elevated expression of IL-1β, NFκB, and TGF-β1.
Interestingly, IL-1β and TNF-α were also decreased in cerebral aneurysms after treatment with Ang (1-7), which protected against aneurysmal rupture in an AT 2 R-dependent manner. 40 Ang (1-7) that is converted by ACE (angiotensinconverting enzyme) from Ang (1-9) or formed from Ang I via neutral endopeptidase, evokes a range of vascular protective effects by activating Mas-and the AT 2 R. 41 Moreover, Masand the AT 2 R form heterodimers and both receptors functionally depend on each other. 42 Therefore, given increased levels of angiotensin precursors by AAA in our study, not only a direct activation of the AT 2 R but generally an activation of the ACE2/Ang-(1-7)/Mas axis, as the counteracting partner of the ACE/Ang I/AT1 receptor 41 might be beneficial by AAA treatment.
Whereas down-regulation of proinflammatory cytokine IL-1β and NFκB are definitely related to the antianeurysmal mechanisms, 43 the regulation of TGF-β in aneurysm is dubious. In thoracic aneurysm, its decrease is beneficial, both in humans and rodents, 44 but in AAA, a neutralization of TGF-β activity was shown to be deleterious. 45 In our study, AI with elastase increased TGF-β1 in serum and aortic tissue. This fact is in agreement with the recent work of Gao et al 46 demonstrating that TGF-β in vascular smooth muscle cell contributes to the pathogenesis of elastase-induced AAA and disruption of TGF-β signaling can prevent aneurysm formation. Given the controversial role of this multifunctional cytokine in aneurysm, further studies should explain different aspects of TGF-β dependent modulations in AAA. Nevertheless, C21 definitively down-regulated TGF-β1, that is in agreement with antifibrotic properties of the AT 2 R shown by cardiac remodeling, 21 L-NAME treated hypertensive rats, 47 in the vessels and the heart of hypertensive rats 19 and in cardiopulmonary fibrosis by pulmonary hypertension. 48 Both, TGF-β and Ang II via its AT1 receptor, are closely associated with aneurysm progression and share similar downstream signaling pathways, including the Smad pathway and the mitogen-activated protein kinase cascades (p38, ERK [extracellular signal-regulated kinase], and JNK/p38). 49 Importantly, AT 2 R signaling opposes AT1-mediated enhancement of TGF-β signaling in thoracic aneurysm through ERK antagonism. 15 We examined TGF-β1 down-stream regulatory transcriptional factors Snai1/SLUG that initiate endothelialmesenchymal transition by vascular remodeling. 50 We found a regulation of SLUG by C21, which may be of importance especially for prevention of cell death. In relation to this, C21 treatment ameliorated the overexpression of pseudokinase MLKL, a trigger and marker of necroptosis -a form of programmed cell death closely linked with inflammation. 51 Thus, antiproteolytic and anti-inflammatory properties of the AT 2 R correspond with inhibition of the process of cell death.
Perspectives
Altogether, AT 2 R stimulation with C21 prevented extracellular matrix degradation, maintained vascular integrity of the aorta and prevented AAA progression. Reduced inflammation and fibrosis, as well as inhibition of proteolytic processes and down-regulation of cell death pathways seem to be involved in protective actions. Whether the AT 2 R stimulation in combination with the AT1 receptor blockade is beneficial by AAA requires further investigations. This study is of clinical relevance because it supports the hypothesis that interfering with the renin-angiotensin system by the AT 2 R agonist might be a novel treatment option in small abdominal aneurysms.
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